News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
529,727 Results
Type
Article (10106)
Company Profile (177)
Press Release (519443)
Multimedia
Podcasts (4)
Webinars (7)
Section
Business (179986)
Career Advice (369)
Deals (27756)
Drug Delivery (9)
Drug Development (61378)
Employer Resources (24)
FDA (10429)
Job Trends (9405)
News (260952)
Policy (19822)
Tag
2027 BioMidwest Elite (1)
2027 Bio NC Standard (1)
2027 Biotech Bay Elite (4)
2027 Biotech Bay Standard (4)
2027 Biotech Beach Elite (1)
2027 Genetown Elite (3)
2027 Genetown Standard (1)
2027 Pharm Country Elite (2)
2027 Pharm Country Standard (2)
Academia (585)
Accelerated approval (29)
ADA (19)
Adcomms (1)
Allergies (118)
Alliances (36625)
ALS (136)
Alzheimer's disease (1086)
Antibody-drug conjugate (ADC) (356)
Approvals (11154)
Artificial intelligence (390)
ASCO (194)
Autoimmune disease (246)
Automation (33)
Bankruptcy (271)
Best Places to Work (7604)
BIO (44)
Biologics (2)
BIOSECURE Act (2)
Biosimilars (161)
BioSpace Insights (18)
Biotechnology (114)
Bladder cancer (155)
Brain cancer (40)
Breast cancer (538)
Cancer (4244)
Cardiovascular disease (257)
Career advice (307)
Career pathing (3)
CAR-T (222)
CDC (2)
Celiac Disease (1)
Cell therapy (572)
Cervical cancer (37)
Clinical research (55929)
Collaboration (1494)
Commercialization (3)
Compensation (1588)
Complete response letters (38)
COVID-19 (942)
CRISPR (65)
C-suite (917)
Cystic fibrosis (95)
Data (6593)
Denatured (4)
Depression (120)
Dermatology (71)
Diabetes (387)
Diagnostics (4321)
Digital health (40)
Diversity (1)
Diversity, equity & inclusion (5)
Drug discovery (194)
Drug pricing (17)
Drug shortages (2)
Duchenne muscular dystrophy (171)
Earnings (78185)
Editorial (4)
Employer branding (3)
Employer resources (23)
Events (95996)
Executive appointments (849)
FDA (13462)
Fibrodysplasia Ossificans Progressiva (10)
Friedreich's ataxia (20)
Frontotemporal dementia (27)
Funding (1092)
Gene editing (132)
Generative AI (15)
Gene therapy (350)
GLP-1 (403)
Government (1143)
Grass and pollen (3)
Guidances (322)
Healthcare (9903)
Hematology (129)
HIV (54)
Huntington's disease (26)
IgA nephropathy (71)
Immunology and inflammation (129)
Immuno-oncology (71)
Indications (180)
Infectious disease (1156)
Inflammatory bowel disease (154)
Inflation Reduction Act (5)
Influenza (94)
Intellectual property (271)
Interviews (50)
IPO (13519)
IRA (5)
Job creations (2198)
Job search strategy (289)
JPM (3)
Kidney cancer (20)
Labor market (1)
Layoffs (87)
Leadership (2)
Legal (5406)
Licensing (9)
Liver cancer (51)
Longevity (18)
Lung cancer (634)
Lymphoma (315)
Machine learning (33)
Management (7)
Manufacturing (679)
Marketing (11)
MASH (165)
Medical device (8757)
Medtech (8903)
Mergers & acquisitions (15350)
Metabolic disorders (840)
mRNA (65)
Multiple sclerosis (135)
NASH (7)
Neurodegenerative disease (267)
Neuropsychiatric disorders (51)
Neuroscience (2142)
NextGen: Class of 2026 (3365)
Non-profit (957)
Now hiring (4)
Obesity (262)
Opinion (32)
Ovarian cancer (169)
Pain (191)
Pancreatic cancer (210)
Parkinson's disease (255)
Partnered (12)
Patents (514)
Patient recruitment (624)
Peanut (45)
People (45186)
Pharmaceutical (40)
Pharmacy benefit managers (8)
Phase 1 (17853)
Phase 2 (25020)
Phase 3 (17133)
Pipeline (8378)
Policy (32)
Postmarket research (1708)
Preclinical (7332)
Press Release (41)
Prostate cancer (222)
Psychedelics (8)
Radiopharmaceuticals (252)
Rare diseases (664)
Real estate (3496)
Recruiting (12)
Regulatory (16927)
Reports (23)
Research institute (694)
Resumes & cover letters (49)
Rett syndrome (41)
RNA editing (5)
RSV (49)
Schizophrenia (140)
Series A (186)
Series B (141)
Service/supplier (5)
Sickle cell disease (68)
Spinal muscular atrophy (95)
Sponsored (8)
Startups (2295)
State (1)
Stomach cancer (3)
Supply chain (56)
Tariffs (7)
Vaccines (405)
Venture capital (23)
Weight loss (92)
Women's health (83)
Worklife (1)
Date
Today (13)
Last 7 days (258)
Last 30 days (1840)
Last 365 days (21789)
2026 (14118)
2025 (21841)
2024 (25734)
2023 (29817)
2022 (38096)
2021 (41036)
2020 (36809)
2019 (26116)
2018 (19677)
2017 (21428)
2016 (20440)
2015 (26745)
2014 (23465)
2013 (19516)
2012 (21438)
2011 (21675)
2010 (21480)
Location
Africa (279)
Alabama (85)
Alaska (2)
Arizona (328)
Arkansas (13)
Asia (24866)
Australia (3036)
California (12727)
Canada (3258)
China (1141)
Colorado (500)
Connecticut (467)
Delaware (322)
Europe (40504)
Florida (1904)
Georgia (388)
Hawaii (3)
Idaho (46)
Illinois (756)
India (68)
Indiana (378)
Iowa (16)
Japan (466)
Kansas (106)
Kentucky (30)
Louisiana (30)
Maine (27)
Maryland (1300)
Massachusetts (8619)
Michigan (310)
Minnesota (585)
Mississippi (4)
Missouri (85)
Montana (20)
Nebraska (12)
Nevada (116)
New Hampshire (64)
New Jersey (3034)
New Mexico (15)
New York (3201)
North Carolina (1462)
North Dakota (4)
Northern California (6447)
Ohio (289)
Oklahoma (19)
Oregon (24)
Pennsylvania (2364)
Puerto Rico (24)
Rhode Island (32)
South America (479)
South Carolina (76)
South Dakota (1)
Southern California (5222)
Tennessee (123)
Texas (1997)
United States (42177)
Utah (373)
Vermont (1)
Virginia (170)
Washington D.C. (41)
Washington State (991)
West Virginia (1)
Wisconsin (84)
Wyoming (1)
529,727 Results for "ngm biopharmaceuticals inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
NGM Bio Announces Closing of Tender Offer
SAN FRANCISCO, April 05, 2024 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (“NGM Bio”) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announced that Atlas Neon Parent, Inc. (“Parent”), an affiliate of The Column Group, LP (“TCG”), through its wholly-owned subsidiary Atlas Neon Merger Sub, Inc. (“Merger Sub”), has successfully completed the previously announced cash tender offer to acquire all outstanding shares o
April 5, 2024
·
4 min read
Press Releases
Sino Biopharmaceutical Limited Unveils New Global Brand, SBP Group, to Accelerate International Expansion
August 19, 2026
·
2 min read
Press Releases
Illuminare Biotechnologies Appoints Veteran Biopharmaceutical Leader as New CEO
July 14, 2026
·
3 min read
Biotech Bay
NGM Bio Announces New Clinical Data from Ongoing Trial of NGM707 in Advanced Solid Tumors and Outlines Evolved Strategy for Aldafermin and NGM120 to Focus on Rare Conditions with Significant Unmet Need
NGM Biopharmaceuticals, Inc. (NGM Bio) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announced encouraging new data from an ongoing Phase 1 Part 1b study evaluating NGM707, a dual ILT2/ILT4 antagonist antibody product candidate, in combination with KEYTRUDA® (pembrolizumab).
January 9, 2024
·
16 min read
Biotech Bay
NGM Bio to Present Two Posters Highlighting Clinical Data from the Ongoing Phase 1/2 Clinical Trial of NGM707, a Dual ILT2/ILT4 Antagonist Antibody Product Candidate, at AACR 2024 Annual Meeting
NGM Biopharmaceuticals, Inc. (NGM Bio) (Nasdaq: NGM) today announced that two abstracts highlighting clinical data from the ongoing Phase 1/2 clinical trial of NGM707, a dual ILT2/ILT4 antagonist antibody product candidate, have been selected for presentation at the American Association for Cancer Research (AACR) Annual Meeting, being held April 5-10, 2024 in San Diego, CA.
March 19, 2024
·
2 min read
Business
NGM Bio Provides Recent Business Highlights and Reports Fourth Quarter and Full Year 2023 Financial Results
NGM Biopharmaceuticals, Inc. (NGM Bio) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today provided recent business highlights and reported financial results for the fourth quarter and full year ended December 31, 2023.
March 11, 2024
·
16 min read
Press Releases
ILC Dover Introduces EZJetFlo™ Technology to Transform Powder Dissolution and Mixing in Biopharmaceutical Manufacturing
August 6, 2026
·
3 min read
Biotech Bay
NGM Bio to Participate in the Cowen 44th Annual Health Care Conference
NGM Biopharmaceuticals, Inc. (Nasdaq: NGM) today announced that David J. Woodhouse, Ph.D., Chief Executive Officer, will participate in a corporate panel discussion on novel oncology targets at the Cowen 44th Annual Health Care Conference on Tuesday, March 5th, at 9:10 am ET.
February 20, 2024
·
1 min read
Press Releases
Lifecore Biomedical Signs Agreement with New Biopharmaceutical Customer
June 2, 2026
·
5 min read
Biotech Bay
NGM Bio to Participate in the B. Riley Securities 4th Annual Oncology Conference
NGM Biopharmaceuticals, Inc. (Nasdaq: NGM) today announced that David J. Woodhouse, Ph.D., Chief Executive Officer, and Jean-Frédéric Viret, Ph.D., Chief Financial Officer, will participate in the B. Riley Securities 4th Annual Oncology Conference and will provide a business update focusing on NGM Bio’s wholly-owned oncology portfolio on Thursday, January 18th, at 2:30 pm ET.
January 17, 2024
·
1 min read
1 of 52,973
Next
